Michael Dunne Reports Direct Purchase of 15,000 ITRM Shares

Rhea-AI Filing Summary

Michael W. Dunne, a director of Iterum Therapeutics plc (ITRM), filed a Form 4 reporting a transaction on 08/08/2025. The filing shows a reported acquisition of 15,000 ordinary shares at $0.7236. Following the transaction, Mr. Dunne beneficially owned 235,001 shares on a direct basis. The Form 4 bears his signature dated 08/12/2025.

Positive

• Director Michael W. Dunne acquired 15,000 ordinary shares at $0.7236 on 08/08/2025
• Beneficial ownership reported as 235,001 shares on a direct basis

Negative

• None.

Insights

Financial Analyst

Small insider purchase disclosed; limited likely market impact but signals director buying.

The Form 4 shows a purchase of 15,000 ordinary shares at $0.7236 on 08/08/2025 by Michael W. Dunne, a director. Beneficial ownership after the transaction is reported as 235,001 shares (direct). This is a routine Section 16 filing reporting insider activity; the transaction size appears modest relative to a typical public float and is unlikely to be materially market-moving.

Corporate Governance Expert

Disclosure appears compliant with Section 16 requirements; no governance issues evident in the filing.

The filing is a standard Form 4 reporting an insider purchase and includes a dated signature (08/12/2025). It identifies the reporting person as a director and reports direct ownership post-transaction. There is no indication in the document of related-party conflicts, derivative activity, or amendments that would raise governance concerns.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dunne Michael W.

(Last) (First) (Middle)

C/O ITERUM THERAPEUTICS PLC

25 NORTH WALL QUAY

(Street)

DUBLIN 1 L2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Iterum Therapeutics plc [ ITRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/08/2025		P		15,000	A	$0.7236	235,001	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Michael W. Dunne	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Michael W. Dunne report on the Form 4 for ITRM?

The Form 4 reports a purchase of 15,000 ordinary shares at $0.7236 on 08/08/2025 and shows 235,001 shares beneficially owned (direct) after the transaction.

When was the Form 4 signed and filed for Iterum Therapeutics (ITRM)?

The Form 4 contains the reporting person’s signature dated 08/12/2025 and reports the transaction date as 08/08/2025.

Does the filing show any derivative securities or option activity for ITRM?

No. The filing’s Table II for derivative securities contains no entries; only a non-derivative ordinary share purchase is reported.

What is Michael W. Dunne’s role at Iterum Therapeutics according to the Form 4?

The Form 4 lists Michael W. Dunne as a Director of Iterum Therapeutics plc.